HRTX News and Press, Heron Therapeutics Inc. From 05/07/24

2024-05-07 08:02:30 ET More on Heron Therapeutics Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain Heron Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript Heron Th...

Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates PR Newswire Net Product Sales of $34.7 million , which increased from $29.6 million for the same period in 2023. Net Loss Per Share $(0.02) , which decreased...

Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...

2024-05-06 10:57:47 ET More on Heron Therapeutics Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain Heron Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript Heron Th...

Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 PR Newswire SAN DIEGO , April 24, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the compa...

Heron Therapeutics, Inc. (NASDAQ: HRTX) is one of today's top gainers. The company's shares have moved 19.5% on the day to $3.1. Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its prop...

2024-04-16 16:24:08 ET Summary HRTX has received approval for its supplemental New Drug Application for Zynrelef, allowing its use in more surgical procedures. The company has partnered with Crosslink Life Sciences to promote Zynrelef, which could further drive sales growth. T...

Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City PR Newswire SAN DIEGO , April 11, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it will host an Investor Day on...

Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference PR Newswire SAN DIEGO , March 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig C...

2024-03-13 15:35:28 ET A California-based %Biotech company saw its shares soar on Wednesday, a day following the company’s Q4 earnings announcement. With analysts expecting a net loss of $0.16 per diluted share, %HeronTherapeutics (Nasdaq: HRTX) Q4 results came in at a net lo...